Menü
Das neue sharewise ist da Übersichtlicher, schneller, mit heller und dunkler Ansicht — und allem, was du kennst. Jetzt ausprobieren
You need to sign in or sign up before continuing.
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Kenvue (KVUE) Q2 Sales Drop 4%


Kenvue (NYSE:KVUE), the consumer health company best known for brands like Tylenol and Band-Aid, reported its earnings for the second quarter on August 7, 2025. The main news from the release: Non-GAAP earnings per share reached $0.29, narrowly beating analyst forecasts of $0.28 (non-GAAP), but GAAP revenue fell to $3.839 billion, slightly below GAAP estimates of $3.85 billion and down from $4.00 billion (GAAP) a year earlier. The period also highlighted positive free cash flow (non-GAAP), even as weak sales impacted all business lines. Management reduced its FY2025 outlook, signaling that tougher times may lie ahead for the company.

Source: Analyst estimates for the quarter provided by FactSet.

Kenvue develops and markets consumer health products across a range of categories. Its lineup covers essential over-the-counter medicines, personal care items, and wellness products -- including household brands like Tylenol (pain relief and fever reducer), Neutrogena (skin care), and Listerine (mouthwash).

Continue reading


Source Fool.com

Like: 0
Teilen

Kommentare